Join the HIV Infection group to help and get support from people like you.
HIV Infection News (Page 7)
Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS
Merck Receives FDA Approval of Isentress HD (raltegravir), a New Once-Daily Option for the Combination Treatment of HIV-1 Infection in Appropriate Patients
KENILWORTH, N.J.-- May 30, 2017 (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living With HIV
Research Triangle Park, NC — On November 4, 2016, ViiV Healthcare received approval from the U.S. Food and Drug Administration (FDA) to market Selzentry for the treatment of only CCR5-tropic HIV-1 i...
U.S. FDA Approves Prezista (darunavir) for Use in Pregnant Women with HIV
TITUSVILLE, N.J., July 18, 2016 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...
FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200...
FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for...
FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection
February 6, 2015 – The United States Food and Drug Administration (FDA) has approved Dutrebis, a fixed dose combination tablet containing 150 mg of lamivudine and 300 mg of raltegravir. Dutrebis...
FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults
TITUSVILLE, N.J., Jan. 29, 2015 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Prezcobix...
FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
PRINCETON, N.J. – January 29, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg...
FDA Approves Tybost (cobicistat) for use in the treatment of HIV-1 Infection
September 24, 2014 – The U.S. Food and Drug Administration (FDA) has approved Tybost (cobicistat), a CYP3A inhibitor used in combination with atazanavir or darunavir for the treatment of human...
FDA Approves Vitekta (elvitegravir) for HIV-1 Infection
September 24, 2014 – The U.S. Food and Drug Administration (FDA) has approved Vitekta (elvitegravir), an integrase strand transfer inhibitor for the combination treatment of human immunodeficiency...
FDA Approves Triumeq for the Treatment of HIV-1 Infection
August 22, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...
FDA Approves Tivicay (dolutegravir) to Treat HIV Infection
August 12, 2013 – The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that...
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of Sustiva (efavirenz) in HIV-1 Infected Pediatric Patients
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Sustiva...
FDA Approves Fulyzaq - First Anti-Diarrheal Drug for HIV/AIDS Patients
December 31, 2012 – The U.S. Food and Drug Administration today approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Pre-Exposure Prophylaxis, Viral Infection
Related drug support groups
Biktarvy, bictegravir / emtricitabine / tenofovir alafenamide, Genvoya, Triumeq